p.93 抽出テキスト

890. Ramlakhan KP, Kauling RM, Schenkelaars N, Segers D, Yap SC, Post MC, et al. Supraventricular arrhythmia in pregnancy. Heart 2022;108:1674–81. https://doi.org/ 10.1136/heartjnl-2021-320451 891. Katritsis DG, Boriani G, Cosio FG, Hindricks G, Jais P, Josephson ME, et al. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Eur Heart J 2017;19:465–511. https://doi. org/10.1093/europace/euw301 892. Moore JS, Teefey P, Rao K, Berlowitz MS, Chae SH, Yankowitz J. Maternal arrhythmia: a case report and review of the literature. Obstet Gynecol Surv 2012;67:298–312. https://doi.org/10.1097/OGX.0b013e318253a76e 893. Wang YC, Chen CH, Su HY, Yu MH. The impact of maternal cardioversion on fetal haemodynamics. Eur J Obstet Gynecol Reprod Biol 2006;126:268–9. https://doi.org/10. 1016/j.ejogrb.2005.11.021 894. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery; Camm AJ, Kirchhof P, Lip GY, Schotten U, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369–429. https:// doi.org/10.1093/eurheartj/ehq278 895. Kockova R, Kocka V, Kiernan T, Fahy GJ. Ibutilide-induced cardioversion of atrial fibrillation during pregnancy. J Cardiovasc Electrophysiol 2007;18:545–7. https://doi.org/ 10.1111/j.1540-8167.2006.00752.x 896. Georgiopoulos G, Tsiachris D, Kordalis A, Kontogiannis C, Spartalis M, Pietri P, et al. Pharmacotherapeutic strategies for atrial fibrillation in pregnancy. Expert Opin Pharmacother 2019;20:1625–36. https://doi.org/10.1080/14656566.2019.1621290 897. Jensen AS, Idorn L, Nørager B, Vejlstrup N, Sondergaard L. Anticoagulation in adults with congenital heart disease: the who, the when and the how? Heart 2015;101: 424–9. https://doi.org/10.1136/heartjnl-2014-305576 898. Pujol C, Niesert AC, Engelhardt A, Schoen P, Kusmenkov E, Pittrow D, et al. Usefulness of direct oral anticoagulants in adult congenital heart disease. Am J Cardiol 2016;117:450–5. https://doi.org/10.1016/j.amjcard.2015.10.062 899. Yang H, Bouma BJ, Dimopoulos K, Khairy P, Ladouceur M, Niwa K, et al. Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study. Int J Cardiol 2020; 299:123–30. https://doi.org/10.1016/j.ijcard.2019.06.014 900. Renda G, Ricci F, Giugliano RP, De Caterina R. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease. J Am Coll Cardiol 2017;69:1363–71. https://doi.org/10.1016/j.jacc.2016.12.038 901. Caldeira D, David C, Costa J, Ferreira JJ, Pinto FJ. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2018;4:111–8. https://doi.org/ 10.1093/ehjcvp/pvx028 902. Ammash NM, Phillips SD, Hodge DO, Connolly HM, Grogan MA, Friedman PA, et al. Outcome of direct current cardioversion for atrial arrhythmias in adults with congenital heart disease. Int J Cardiol 2012;154:270–4. https://doi.org/10.1016/j.ijcard.2010.09. 028 903. Feltes TF, Friedman RA. Transesophageal echocardiographic detection of atrial thrombi in patients with nonfibrillation atrial tachyarrhythmias and congenital heart disease. J Am Coll Cardiol 1994;24:1365–70. https://doi.org/10.1016/0735-1097(94)90121-X 904. Roos-Hesselink JW, Meijboom FJ, Spitaels SE, van Domburg R, van Rijen EH, Utens EM, et al. Excellent survival and low incidence of arrhythmias, stroke and heart failure longterm after surgical ASD closure at young age. A prospective follow-up study of 21–33 years. Eur Heart J 2003;24:190–7. https://doi.org/10.1016/S0195-668X(02)00383-4 905. Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 2017;377:1011–21. https://doi.org/10.1056/NEJMoa1705915 906. Gutierrez SD, Earing MG, Singh AK, Tweddell JS, Bartz PJ. Atrial tachyarrhythmias and the Cox-Maze procedure in congenital heart disease. Congenit Heart Dis 2013;8:434–9. https://doi.org/10.1111/chd.12031 907. Kobayashi J, Yamamoto F, Nakano K, Sasako Y, Kitamura S, Kosakai Y. Maze procedure for atrial fibrillation associated with atrial septal defect. Circulation 1998;98:II399–402. 908. Shim H, Yang JH, Park PW, Jeong DS, Jun TG. Efficacy of the Maze procedure for atrial fibrillation associated with atrial septal defect. Korean J Thorac Cardiovasc Surg 2013;46: 98–103. https://doi.org/10.5090/kjtcs.2013.46.2.98 909. Sherwin ED, Triedman JK, Walsh EP. Update on interventional electrophysiology in congenital heart disease: evolving solutions for complex hearts. Circ Arrhythm Electrophysiol 2013;6:1032–40. https://doi.org/10.1161/CIRCEP.113.000313 910. Chiha M, Samarasinghe S, Kabaker AS. Thyroid storm: an updated review. J Intensive Care Med 2015;30:131–40. https://doi.org/10.1177/0885066613498053 911. Y-Hassan S, Falhammar H. Cardiovascular manifestations and complications of pheochromocytomas and paragangliomas. J Clin Med 2020;9:2435. https://doi.org/10.3390/ jcm9082435 912. Baumgartner C, da Costa BR, Collet TH, Feller M, Floriani C, Bauer DC, et al. Thyroid function within the normal range, subclinical hypothyroidism, and the risk of atrial fibrillation. Circulation 2017;136:2100–16. https://doi.org/10.1161/CIRCULATIONAHA. 117.028753 913. Huang M, Yang S, Ge G, Zhi H, Wang L. Effects of thyroid dysfunction and the thyroidstimulating hormone levels on the risk of atrial fibrillation: a systematic review and dose-response meta-analysis from cohort studies. Endocr Pract 2022;28:822–31. https://doi.org/10.1016/j.eprac.2022.05.008 914. Shin DG, Kang MK, Han D, Choi S, Cho JR, Lee N. Enlarged left atrium and decreased left atrial strain are associated with atrial fibrillation in patients with hyperthyroidism irrespective of conventional risk factors. Int J Cardiovasc Imaging 2022;38:613–20. https://doi.org/10.1007/s10554-021-02450-6 915. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249–52. https://doi.org/10.1056/NEJM199411103311901 916. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229–361. https://doi.org/10.1093/eurheartj/ehac244 917. El Sabbagh R, Azar NS, Eid AA, Azar ST. Thyroid dysfunctions due to immune checkpoint inhibitors: a review. Int J Gen Med 2020;13:1003–9. https://doi.org/10.2147/IJGM. S261433 918. Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FD, Wilson S, et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med 2007;167:928–34. https://doi.org/10.1001/archinte.167.9.928 919. Selmer C, Olesen JB, Hansen ML, Lindhardsen J, Olsen AM, Madsen JC, et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ 2012;345:e7895. https://doi.org/10.1136/bmj.e7895 920. Kim K, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, et al. Increased risk of ischemic stroke and systemic embolism in hyperthyroidism-related atrial fibrillation: a nationwide cohort study. Am Heart J 2021;242:123–31. https://doi.org/10.1016/j.ahj.2021.08.018 921. Zhang J, Bisson A, Fauchier G, Bodin A, Herbert J, Ducluzeau PH, et al. Yearly incidence of stroke and bleeding in atrial fibrillation with concomitant hyperthyroidism: a national discharge database study. J Clin Med 2022;11:1342. https://doi.org/10.3390/ jcm11051342 922. Bartalena L, Bogazzi F, Chiovato L, Hubalewska-Dydejczyk A, Links TP, Vanderpump M. 2018 European Thyroid Association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction. Eur Thyroid J 2018;7:55–66. https://doi. org/10.1159/000486957 923. Cappellani D, Papini P, Di Certo AM, Morganti R, Urbani C, Manetti L, et al. Duration of exposure to thyrotoxicosis increases mortality of compromised AIT patients: the role of early thyroidectomy. J Clin Endocrinol Metab 2020;105:dgaa464. https://doi. org/10.1210/clinem/dgaa464 924. Trevisan C, Piovesan F, Lucato P, Zanforlini BM, De Rui M, Maggi S, et al. Parathormone, vitamin D and the risk of atrial fibrillation in older adults: a prospective study. Nutr Metab Cardiovasc Dis 2019;29:939–45. https://doi.org/10.1016/j.numecd. 2019.05.064 925. Pepe J, Cipriani C, Curione M, Biamonte F, Colangelo L, Danese V, et al. Reduction of arrhythmias in primary hyperparathyroidism, by parathyroidectomy, evaluated with 24-h ECG monitoring. Eur J Endocrinol 2018;179:117–24. https://doi.org/10.1530/ EJE-17-0948 926. Pepe J, Cipriani C, Sonato C, Raimo O, Biamonte F, Minisola S. Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur J Endocrinol 2017; 177:R297–308. https://doi.org/10.1530/EJE-17-0485 927. Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018;6:41–50. https://doi.org/10.1016/S2213-8587(17)30319-4 928. Bollati M, Lopez C, Bioletto F, Ponzetto F, Ghigo E, Maccario M, et al. Atrial fibrillation and aortic ectasia as complications of primary aldosteronism: focus on pathophysiological aspects. Int J Mol Sci 2022;23:2111. https://doi.org/10.3390/ijms23042111 929. Kim KJ, Hong N, Yu MH, Lee H, Lee S, Lim JS, et al. Time-dependent risk of atrial fibrillation in patients with primary aldosteronism after medical or surgical treatment initiation. Hypertension 2021;77:1964–73. https://doi.org/10.1161/HYPERTENSIONA HA.120.16909 930. Larsson SC, Lee WH, Burgess S, Allara E. Plasma cortisol and risk of atrial fibrillation: a Mendelian randomization study. J Clin Endocrinol Metab 2021;106:e2521–6. https://doi. org/10.1210/clinem/dgab219 931. Di Dalmazi G, Vicennati V, Pizzi C, Mosconi C, Tucci L, Balacchi C, et al. Prevalence and incidence of atrial fibrillation in a large cohort of adrenal incidentalomas: a long-term study. J Clin Endocrinol Metab 2020;105:dgaa270. https://doi.org/10.1210/clinem/ dgaa270 932. Hong S, Kim KS, Han K, Park CY. Acromegaly and cardiovascular outcomes: a cohort study. Eur Heart J 2022;43:1491–9. https://doi.org/10.1093/eurheartj/ehab822 933. Polina I, Jansen HJ, Li T, Moghtadaei M, Bohne LJ, Liu Y, et al. Loss of insulin signaling may contribute to atrial fibrillation and atrial electrical remodeling in type 1 diabetes. Downloaded from academic.oup.com/eurheartj/article/45/36/3314/7738779 by guest on 07 October 2026